Organization
CSPC Zhongnuo Pharmaceutical
8 clinical trials
Clinical trial
A Randomized, Multi-center, Open-label Phase III Bridging Study to Compare Efficacy of Liposomal Cytarabine-Daunorubicin for Injection With Cytarabine and Daunorubicin in Treating Older Patients With High-Risk (Secondary) Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2026-02-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2053 in Subjects With Normal or Elevated Low-Density Lipoprotein CholesterolStatus: Not yet recruiting, Estimated PCD: 2024-08-30
Clinical trial
A Randomized, Double-blind, Active-compared Phase Ш Clinical Trial to Evaluate Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergencyStatus: Not yet recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple SclerosisStatus: Withdrawn, Estimated PCD: 2022-11-08
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)Status: Not yet recruiting, Estimated PCD: 2024-10-15
Clinical trial
A Randomized, Open-label, Two-period, Two-way Crossover Bioequivalence Study of Two (Cytarabine: Daunorubicin) Liposome for Injection in Elderly AML SubjectsStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized, Open-label, Positive-controlled, Multicenter Phase Ш Study Comparing Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing TherapyStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Randomized, Open-label, Single-dose, Two-preparation, Two-period, Two-sequence Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-09-01